Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS
BackgroundRecent studies proposed cellular immunoprofiling as a surrogate for predicting treatment response and/or stratifying the occurrence of adverse events (AEs) in persons with multiple sclerosis (pwMS). However, applicability in real-world circumstances is not sufficiently addressed.ObjectiveW...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1388941/full |
| _version_ | 1827281376558186496 |
|---|---|
| author | Tobias Zrzavy Tobias Zrzavy Kerstin Rieder Kerstin Rieder Viktoria Wuketich Viktoria Wuketich Renate Thalhammer Helmuth Haslacher Patrick Altmann Patrick Altmann Barbara Kornek Barbara Kornek Nik Krajnc Nik Krajnc Tobias Monschein Tobias Monschein Christiane Schmied Christiane Schmied Karin Zebenholzer Karin Zebenholzer Gudrun Zulehner Gudrun Zulehner Thomas Berger Thomas Berger Paulus Rommer Paulus Rommer Fritz Leutmezer Fritz Leutmezer Gabriel Bsteh Gabriel Bsteh |
| author_facet | Tobias Zrzavy Tobias Zrzavy Kerstin Rieder Kerstin Rieder Viktoria Wuketich Viktoria Wuketich Renate Thalhammer Helmuth Haslacher Patrick Altmann Patrick Altmann Barbara Kornek Barbara Kornek Nik Krajnc Nik Krajnc Tobias Monschein Tobias Monschein Christiane Schmied Christiane Schmied Karin Zebenholzer Karin Zebenholzer Gudrun Zulehner Gudrun Zulehner Thomas Berger Thomas Berger Paulus Rommer Paulus Rommer Fritz Leutmezer Fritz Leutmezer Gabriel Bsteh Gabriel Bsteh |
| author_sort | Tobias Zrzavy |
| collection | DOAJ |
| description | BackgroundRecent studies proposed cellular immunoprofiling as a surrogate for predicting treatment response and/or stratifying the occurrence of adverse events (AEs) in persons with multiple sclerosis (pwMS). However, applicability in real-world circumstances is not sufficiently addressed.ObjectiveWe aimed to explore whether standard routine clinical leukocyte phenotyping before treatment initiation could help stratify patients according to treatment response or AEs in a real-world MS cohort.MethodsIn this retrospective study, 150 pwMS were included, who had been newly initiated on a disease-modifying drug (DMD) and had been assessed for standard immunophenotyping before DMD initiation (baseline) and at least once during the following year. Multivariate models were used to assess an association of immune subsets and the association between immune cell profiles regarding treatment response and AEs.ResultsWe found that the composition of T cell subsets was associated with relapse activity, as an increased proportion of CD8+ lymphocytes at baseline indicated a higher likelihood of subsequent relapse (about 9% per 1% increase in CD8+ proportion of all CD3+ cells). This was particularly driven by patients receiving anti-CD20 therapy, where also EDSS worsening was associated with a higher number of CD8+ cells at baseline (3% increase per 10 cells). In the overall cohort, an increase in the proportion of NK cells was associated with a higher risk of EDSS worsening (5% per 1% increase). Occurrence of AEs was associated with a higher percentage of T cells and a lower number of percentual NKT cells at baseline.ConclusionImmune cell profiles are associated with treatment response and the occurrence of AEs in pwMS. Hence, immunophenotyping may serve as a valuable biomarker to enable individually tailored treatment strategies in pwMS. |
| first_indexed | 2024-04-24T08:59:12Z |
| format | Article |
| id | doaj.art-f1da4e070204403483fdf521afd7941e |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-24T08:59:12Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-f1da4e070204403483fdf521afd7941e2024-04-16T04:30:20ZengFrontiers Media S.A.Frontiers in Neurology1664-22952024-04-011510.3389/fneur.2024.13889411388941Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy0Tobias Zrzavy1Kerstin Rieder2Kerstin Rieder3Viktoria Wuketich4Viktoria Wuketich5Renate Thalhammer6Helmuth Haslacher7Patrick Altmann8Patrick Altmann9Barbara Kornek10Barbara Kornek11Nik Krajnc12Nik Krajnc13Tobias Monschein14Tobias Monschein15Christiane Schmied16Christiane Schmied17Karin Zebenholzer18Karin Zebenholzer19Gudrun Zulehner20Gudrun Zulehner21Thomas Berger22Thomas Berger23Paulus Rommer24Paulus Rommer25Fritz Leutmezer26Fritz Leutmezer27Gabriel Bsteh28Gabriel Bsteh29Department of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Vienna, AustriaComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaBackgroundRecent studies proposed cellular immunoprofiling as a surrogate for predicting treatment response and/or stratifying the occurrence of adverse events (AEs) in persons with multiple sclerosis (pwMS). However, applicability in real-world circumstances is not sufficiently addressed.ObjectiveWe aimed to explore whether standard routine clinical leukocyte phenotyping before treatment initiation could help stratify patients according to treatment response or AEs in a real-world MS cohort.MethodsIn this retrospective study, 150 pwMS were included, who had been newly initiated on a disease-modifying drug (DMD) and had been assessed for standard immunophenotyping before DMD initiation (baseline) and at least once during the following year. Multivariate models were used to assess an association of immune subsets and the association between immune cell profiles regarding treatment response and AEs.ResultsWe found that the composition of T cell subsets was associated with relapse activity, as an increased proportion of CD8+ lymphocytes at baseline indicated a higher likelihood of subsequent relapse (about 9% per 1% increase in CD8+ proportion of all CD3+ cells). This was particularly driven by patients receiving anti-CD20 therapy, where also EDSS worsening was associated with a higher number of CD8+ cells at baseline (3% increase per 10 cells). In the overall cohort, an increase in the proportion of NK cells was associated with a higher risk of EDSS worsening (5% per 1% increase). Occurrence of AEs was associated with a higher percentage of T cells and a lower number of percentual NKT cells at baseline.ConclusionImmune cell profiles are associated with treatment response and the occurrence of AEs in pwMS. Hence, immunophenotyping may serve as a valuable biomarker to enable individually tailored treatment strategies in pwMS.https://www.frontiersin.org/articles/10.3389/fneur.2024.1388941/fullMSimmunophenotypingDMDtreatmentT cells |
| spellingShingle | Tobias Zrzavy Tobias Zrzavy Kerstin Rieder Kerstin Rieder Viktoria Wuketich Viktoria Wuketich Renate Thalhammer Helmuth Haslacher Patrick Altmann Patrick Altmann Barbara Kornek Barbara Kornek Nik Krajnc Nik Krajnc Tobias Monschein Tobias Monschein Christiane Schmied Christiane Schmied Karin Zebenholzer Karin Zebenholzer Gudrun Zulehner Gudrun Zulehner Thomas Berger Thomas Berger Paulus Rommer Paulus Rommer Fritz Leutmezer Fritz Leutmezer Gabriel Bsteh Gabriel Bsteh Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS Frontiers in Neurology MS immunophenotyping DMD treatment T cells |
| title | Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS |
| title_full | Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS |
| title_fullStr | Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS |
| title_full_unstemmed | Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS |
| title_short | Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS |
| title_sort | immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with ms |
| topic | MS immunophenotyping DMD treatment T cells |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2024.1388941/full |
| work_keys_str_mv | AT tobiaszrzavy immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT tobiaszrzavy immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT kerstinrieder immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT kerstinrieder immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT viktoriawuketich immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT viktoriawuketich immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT renatethalhammer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT helmuthhaslacher immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT patrickaltmann immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT patrickaltmann immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT barbarakornek immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT barbarakornek immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT nikkrajnc immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT nikkrajnc immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT tobiasmonschein immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT tobiasmonschein immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT christianeschmied immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT christianeschmied immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT karinzebenholzer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT karinzebenholzer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT gudrunzulehner immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT gudrunzulehner immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT thomasberger immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT thomasberger immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT paulusrommer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT paulusrommer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT fritzleutmezer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT fritzleutmezer immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT gabrielbsteh immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms AT gabrielbsteh immunophenotypinginroutineclinicalpracticeforpredictingtreatmentresponseandadverseeventsinpatientswithms |